Pixium Vision announces the termination of its convertible debenture financing agreement with US healthcare investor ESGO

• Termination will not trigger any penalties from Pixium Vision
• The first financing tranche of €5.5 million was drawn down in July 2022

Paris, France, January 13, 2023 – 21:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemonic: ALPIX), a bioelectronics company developing innovative bionic vision systems to help patients who have lost their sight to live more independently, today announces its termination its convertible debenture financing agreement with the European Select Growth Opportunities Fund (the “Investor” or “ESGO”), a US-based investor specializing in healthcare.

Termination of the contract will not trigger any penalties from Pixium Vision according to the terms of the contract.

The agreement for a maximum nominal amount of EUR 30 million in Notes redeemable for cash and/or new shares (the “Remarks”), interest-free and without warrants, over a maximum period of 36 months July 2022. The first tranche of 550 bonds with a nominal value of EUR 5.5 million was issued by the company and subscribed by the investor on July 13, 2022. 316 Notes are currently outstanding and unconverted, representing €3.16 million and are convertible or redeemable at 109% cash until July 13, 2023. Any outstanding tranche warrants will terminate immediately

Pixium Vision’s cash runway extends through the end of Q2 2023 and the company is exploring various avenues to secure its cash flow needed to pursue its strategic ambitions.

Around Pixium Vision

Pixium Vision creates a world of bionic vision for people who have lost their sight, allowing them to regain visual perception and more autonomy. Pixium Vision’s bionic vision systems involve a surgical procedure and a rehabilitation period. Prima System Subretinal Miniature Photovoltaic Wireless…